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Abstract The European Forsteo Observational Study was
designed to examine the effectiveness of teriparatide in
postmenopausal women with osteoporosis treated for up to
18 months in normal clinical practice in eight European
countries. The incidence of clinical vertebral and nonver-
tebral fragility fractures, back pain, and health-related
quality of life (HRQoL, EQ-5D) were assessed. Sponta-
neous reports of adverse events were collected. All 1,648
enrolled women were teriparatide treatment-naive, 91.0%
of them had previously received other anti-osteoporosis
drugs, and 72.8% completed the 18-month study. A total of
168 incident clinical fractures were sustained by 138
(8.8%) women (821 fractures/10,000 patient-years). A 47%
decrease in the odds of fracture in the last 6-month period
compared to the ﬁrst 6-month period was observed
(P\0.005). Mean back pain VAS was reduced by
25.8 mm at end point (P\0.001). Mean change from
baseline in EQ-VAS was 13 mm by 18 months. The largest
improvements were reported in the EQ-5D subdomains of
usual activities and pain/discomfort. There were 365
adverse events spontaneously reported, of which 48.0%
were considered related to teriparatide; adverse events
were the reason for discontinuation for 79 (5.8%) patients.
In conclusion, postmenopausal women with severe osteo-
porosis who were prescribed teriparatide in standard clin-
ical practice had a signiﬁcant reduction in the incidence of
fragility fractures and a reduction in back pain over an 18-
month treatment period. This was associated with a clini-
cally signiﬁcant improvement in HRQoL. Safety was
consistent with current prescribing information. These
results should be interpreted in the context of the open-
label, noncontrolled design of the study.
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Osteoporosis, a chronic skeletal disorder characterized by
reduced bone quantity and quality, increases bone fragility
and predisposes patients to fractures, mainly at the spine,
hip, wrist, and proximal humerus. In the year 2000, the
number of osteoporotic fractures worldwide was estimated
to be 9 million, with 61% of these occurring in women [1].
Osteoporotic fractures substantially impair health-related
quality of life (HRQoL) [2, 3] and lead to increased
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DOI 10.1007/s00223-009-9299-6morbidity and, depending on fracture location, increased
mortality [4]. A recent estimate put the projected costs of
treating osteoporotic fractures in women in Europe at
€76.7 billion by 2050 [5].
Recently approved drugs for the treatment of osteopo-
rosis have been shown to reduce the risk of vertebral and
nonvertebral fractures [6, 7]. Currently, the most com-
monly prescribed medications for osteoporosis are antire-
sorptive agents, primarily bisphosphonates. Teriparatide is
a recombinant human N-terminal fragment of parathyroid
hormone (rhPTH [1–34]), a bone anabolic agent that has
been shown to increase bone mass and strength. In a pla-
cebo-controlled clinical trial, teriparatide reduced the rel-
ative risk of new vertebral and nonvertebral fragility
fractures after 19 months of treatment by 65% and 53%,
respectively, in postmenopausal women with severe oste-
oporosis [8]. Treatment with teriparatide resulted in a
greater increase in bone mineral density (BMD) and
reduction in vertebral fracture risk than alendronate in men
and women with glucocorticoid-induced osteoporosis [9].
Although randomized controlled trials are considered
the gold standard for investigating drug efﬁcacy, their
design limits the capacity to provide answers to questions
about more ‘‘typical’’ patient populations and issues found
only in clinical practice. In a recent retrospective chart
review of 120 patients, it was estimated that approximately
80% of patients receiving treatment for osteoporosis would
not be eligible for inclusion in a randomized controlled
trial because of comorbidities, previous treatment with
bone-active agents, or the use of other medications [10].
Observational studies can be an important addition to a
clinician’s resources by complementing randomized con-
trolled trial data with information on the effectiveness and
compliance of a treatment used in routine clinical care in
larger and more diverse patient populations [11]. It is well
known that compliance with osteoporosis treatments is
higher in clinical trials than in normal clinical practice [12].
This is important as it may inﬂuence not only the expected
outcome of the treatment in the individual patient [13]b u t
also the pharmacoeconomic considerations.
In 2006, the prospective European Forsteo Observa-
tional Study (EFOS) was set up to observe the effects of
teriparatide treatment for up to 18 months, with a post-
treatment follow-up period of a further 18 months’ dura-
tion, in postmenopausal women with osteoporosis. The
patients prescribed teriparatide in the EFOS were severely
osteoporotic, with a high fracture risk and poor HRQoL,
despite previous therapy for osteoporosis; moderate to
severe back pain was also very common [14]. Here, we
describe the incidence of clinical vertebral and nonverte-
bral fragility fractures, the occurrence of back pain and
changes in HRQoL, and the compliance with teriparatide
during 18 months of treatment.
Patients and Methods
Study Design
The study design and characteristics of the patient popu-
lation have been described [14]. Brieﬂy, 1,648 postmeno-
pausal women with a diagnosis of osteoporosis who were
about to initiate teriparatide treatment were enrolled in
eight European countries. Patients were excluded from the
study if they were currently being treated with an investi-
gational drug or procedure or had any contraindications as
described in the teriparatide label. Apart from this, the
study was purely observational and there were no further
restrictions for the selection of the patients. All patients
gave written informed consent prior to enrollment and were
able to withdraw without consequence at any time. The
study was approved by local ethics committees or review
boards, depending on local requirements.
Data Collection
At the baseline visit, patient demographic characteristics,
risk factors for osteoporosis and falls, osteoporosis thera-
pies, and disease status were recorded [14]. The women
attended visits at baseline and at approximately 3, 6, 12,
and 18 months after teriparatide initiation. Patients were
observed for the entire duration of treatment, and compli-
ance with treatment was assessed from their reporting of
the number of missed doses in the month prior to each visit.
Incident clinical vertebral and nonvertebral fractures,
the primary study end point, were diagnosed and conﬁrmed
by review of the original X-rays and/or the radiology or
surgical reports at the investigational site. A new or
worsened vertebral fracture was deﬁned from the presence
of a conﬁrmed radiographic vertebral fracture associated
with signs and/or symptoms, such as acute or severe back
pain, suggestive of a vertebral fracture as described by
Ross [15].
A study-speciﬁc back pain questionnaire (Appendix 1)
was completed at each visit. Perceived severity of back
pain was also evaluated on a horizontal 100 mm Visual
Analogue Scale (VAS) ranging from 0 mm (no back pain)
to 100 mm (worst possible back pain).
HRQoL was measured using the European Quality of
Life Questionnaire (EQ-5D, formerly EuroQol) [16]. EQ-
5D is a generic HRQoL questionnaire that evaluates ﬁve
dimensions of health (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression), each scored on a
three-point scale (no problems, some problems, extreme
problems) plus a visual analogue scale (EQ-VAS), which
assesses the patient-perceived overall health status, on a
scale from 0 mm (worst imaginable health state) to
100 mm (best imaginable health state). The Health State
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123Value (HSV) was calculated from the ﬁve EQ-5D dimen-
sions using the U.K. scoring algorithm for all countries, to
allow for comparisons across countries [17]. Spontaneously
reported adverse events were collected throughout the
study.
Statistical Analysis
Descriptive statistics such as frequencies, percentages,
means, and standard deviations (SD) were used to describe
the study population over time. Incident fractures, back
pain, and quality of life results were summarized over the
teriparatide treatment period and after completion of
18 months of treatment. The number of fractures occurring
in patients receiving teriparatide treatment was summa-
rized in 6-month intervals up to 18 months of treatment. A
logistic regression analysis was used to assess the change
in the number of patients with one or more fractures over
time [18, 19]. Patients were included in the model at all
observed intervals, regardless of whether or not they frac-
tured during a previous interval. The repeated observations
of each patient were assumed to be related, but no further
assumptions were made about the relationship. Contrasts
were made between the odds of fracture in the ﬁrst
6 months of treatment (0–6 months) and each subsequent
6-month period (6–12 months and 12–18 months). Unad-
justed and adjusted models including age, prior bis-
phosphonate use, and a history of fracture in the last
12 months before starting teriparatide were performed.
Fracture modeling was repeated for all vertebral, nonver-
tebral, and main nonvertebral (forearm/wrist, hip, humerus,
leg, and sternum/ribs) fractures.
The number and percent of patients with improvement,
no change, or worsening in each domain of the EQ-5D
questionnaire were summarized at each visit. The sign test
was used to determine whether signiﬁcantly more patients
showed improvement as opposed to worsening.
Back pain changes from baseline in the VAS were
analyzed using a mixed model for repeated measures
(MMRM), adjusting for baseline back pain VAS, age,
diagnosis of rheumatoid arthritis, duration of prior bis-
phosphonate therapy, and history of fracture in the
12 months prior to entering the study. P values represent
the unique inﬂuence of the corresponding factor after
adjustment for all other factors in the model. The number
of patients reporting an improvement or worsening in the
severity, frequency, limitation of activities, and number of
days in bed (B2 days, no change) was analyzed using the
sign test. A similar MMRM was used to assess the change
from baseline in EQ-VAS, including its baseline value. The
EQ-5D HSV had a continuous, nonparametric, bimodal
distribution; therefore, the Wilcoxon sign-rank test was
used to assess changes from baseline in this parameter.
Results
Patient Disposition and Osteoporosis Treatment
A total of 1,648 patients entered the study and were ana-
lyzed at baseline. Mean (SD) age was 71.5 (8.4) years,
body mass index (BMI) was 25.1 (4.4) kg/m
2, and 12.8%
of the patients were current smokers. A previous fracture
after the age of 40 years was reported for 91.9% of the
women, the mean (SD) number of prevalent fractures at
baseline was 2.9 (2.0), and 70% had two or more vertebral
deformities. Approximately 48% of the women had sus-
tained a fragility fracture within the 12 months prior to
starting teriparatide treatment. Rheumatoid arthritis was
the most frequently reported comorbidity (11.9% of the
patients). Only 7.7% of the patients were osteoporosis
treatment–naive, alendronate being the most frequently
used previous treatment (43.6% of the subjects; for more
details, see [14]). Once teriparatide was started, 5.2% of the
patients reported concomitant use of an antiresorptive drug.
Calcium and vitamin D supplements were taken by 74–
78% of patients during the course of the study. By the 18-
month visit, concomitant use of antiresorptives was
reported by 6.3% of the patients, calcitonin being the
antiresorptive drug most frequently used (2.3% of the
patients).
There were 1,577 patients (95.7%) who returned for at
least one follow-up visit and 1,356 (82.3%) who completed
a ﬁnal visit either at 18 months or earlier. There were 79
(5.8%) discontinuations from teriparatide due to adverse
events; the other main reasons for treatment discontinua-
tion were patient decision (n = 109, 8.0%) and physician
decision (n = 26, 1.9%).
At the time of this analysis data lock, the duration of
teriparatide treatment ranged 1–639 days (mean [SD] 461
[166] days). The proportions of patients known to be still
taking teriparatide after 12, 17, and 18 months were 77.0%,
61.5%, and 22%, respectively (Fig. 1). During the
18 months of treatment, 11.9% of patients reported one or
more interruptions to treatment of 4 or more weeks. The
median self-reported number of missing daily injections
during the last month of treatment was three.
Fracture Incidence
Table 1 shows the incidence of fractures during the course
of the study. During follow-up, 138 (8.8%) women sus-
tained a total of 168 incident fractures, giving an overall
fracture rate of 821/10,000 patient-years. Twenty-three
patients (1.5%) sustained two or more new fractures. Of the
168 fractures, 38.7% were clinical vertebral fractures and
61.3% were nonvertebral; 50.6% of all fractures occurred
at the main nonvertebral sites (forearm/wrist [n = 26], hip
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123[n = 21], leg [n = 15], sternum/ribs [n = 12], and
humerus [n = 11]). A history of fracture in the prior 12-
month period did not have a statistically signiﬁcant effect
on the risk of ﬁrst fracture that occurred on teriparatide
treatment (hazard ratio [HR] = 1.37, 95% conﬁdence
interval [CI] 0.97–1.95, P = 0.076).
Overall, the number of patients who had at least one
fracture during teriparatide treatment signiﬁcantly
decreased between the ﬁrst 6-month period (n = 72, 4.6%)
and the second 6-month period (n = 45, 3.5%) (adjusted
model odds ratio [OR] = 0.68, 95% CI 0.47–0.98,
P = 0.038)andbetweentheﬁrst6-monthperiodandthelast
6-month period on treatment (n = 33, 2.8%) (OR = 0.53,
95% CI 0.35–0.82, P = 0.004) (Table 1). The fracture
incidence per 10,000 patient-years of 1,113 in the ﬁrst
6 months decreased to 583 during the 12–18 month period
(Table 1). A decline in the incidence of both clinical ver-
tebral and nonvertebral fractures was observed during the
study (Fig. 2). The clinical vertebral and main nonvertebral
fracture rates were signiﬁcantly decreased between the ﬁrst
6-month period and the last 6-month period on treatment
(Fig. 2).
Back Pain
The mean (SD) back pain measured by the VAS at baseline
was 57.7 (26.6) mm, and this was reduced by 25.8 mm
after 18 months of treatment (P\0.001). The greatest
reduction in back pain, analyzed using the MMRM,
occurred during the ﬁrst 6 months of treatment (Fig. 3).
From the parameters included in the MMRM, only two
variables had a potential inﬂuence on the changes in back
pain VAS (P\0.001); for each additional 5 mm in the
baseline VAS value the change after treatment was 2.8 mm
less, and for every 5 years of prior bisphosphonate therapy
it was 4.4 mm greater.
Table 2 shows the frequency and severity of back pain
during the previous month at each assessment. The fre-
quency of back pain decreased over the treatment period; at
baseline 65.8% of patients reported experiencing back pain
everydayoralmosteveryday,andthisdecreasedto29.9%of
patients after completing 18 months of treatment. At every
postbaselinevisit,thereweresigniﬁcantlymorepatientswho
reported a decrease in the frequency of back pain compared
withbaselinethanthosereportinganincreaseinfrequencyof
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Table 1 Overall risk of incident fractures during treatment with teriparatide
Observation period Fractures per 10,000
patient-years
Total number of
fractures
Patients with
C1 fracture (n [%])
Odds of fracture
a
(95% CI)
OR
a,b (95% CI) P
a
0–6 months (n = 1,560) 1,113 83 72 (4.6) 0.040 (0.030–0.054) –
6–12 months (n = 1,302) 768 50 45 (3.5) 0.027 (0.019–0.039) 0.68 (0.47–0.98) 0.038
12–18 months (n = 1,200) 583 35 33 (2.8) 0.021 (0.014–0.031) 0.53 (0.35–0.82) 0.004
Total (n = 1,577) 821 168 138 (8.8)
c –
n, number of patients who attended observation
a Adjusted model by age, prior bisphosphonate use, and history of fracture in the 12 months before starting teriparatide
b Compared with 0–6 months
c As some patients experienced a fracture in more than one time interval, the total was not the sum of the number of patients with a fracture in
each interval
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123back pain (sign test, P\0.001). The severity of back pain
also decreased during the treatment period; at baseline
moderate/severepainwasreportedby89.2%ofpatients,and
this was reduced to 57.2% after 18 months. At every post-
baseline visit, signiﬁcantly more patients had a decrease in
the severity of back pain than those with an increase (sign
test,P\0.001).Thelimitationonactivityandthefrequency
ofdaysinbedduetobackpainalsodecreasedoverthecourse
of the study (P\0.001) (Table 2).
After18 months,fewerpatientsreportedtheneedtoassist
themselves with their arms when standing up from a chair
(54.6%) compared with baseline (62.9%) (P\0.001).
HRQoL
The mean (SD) EQ-VAS at baseline was 51.7 (22.0) mm.
There was a signiﬁcant increase in adjusted mean EQ-VAS
values from baseline at all visits, and the increase was
13 mm at 18 months (Fig. 4). In the MMRM, the baseline
EQ-VAS value, duration of prior bisphosphonate therapy,
rheumatoid arthritis, and age all had a potential inﬂuence
on the change in HRQoL. For every 5 years of bis-
phosphonate therapy the change in EQ-VAS decreased by
2.2 mm (P\0.001), for every 5 years of increased age the
change in EQ-VAS decreased by 1.2 mm (P\0.001), and
for those with rheumatoid arthritis the change in EQ-VAS
was 5.2 mm less than for those without this disorder.
Table 3 shows that, overall, there was a signiﬁcant
improvement in each of the ﬁve domains of the EQ-5D
(P\0.001). The decrease in the percentage of subjects
reporting some/extreme problems was most pronounced in
the usual activities and pain/discomfort domains.
Results from the EQ-5D HSV scores are also shown in
Table 3. Median (Q1, Q3) HSV scores showed that patients
experienced a signiﬁcant improvement in HRQoL from
baseline (0.59, range 0.08–0.73) to 18 months (0.73, range
0.59–0.85) of teriparatide treatment (Wilcoxon rank test
P\0.001).
Safety
There was a total of 365 adverse events spontaneously
reported by the participant physicians; of these, 135 (37%)
were serious and 175 (48.0%) were considered related to
use of the drug. The most common adverse events were
nausea (5.5%), headache (4.4%), fatigue, and depression
(2.7% each). There were four spontaneous reports of
hypercalcemia, one of which was considered severe as it
resulted in prolonged hospitalization. There were 27 deaths
during the study period, representing 1.6% of the EFOS
cohort. The treating physicians did not consider any death
to be drug-related.
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With the increasingly aging population, osteoporosis is
becoming more prevalent and observational studies are
essential to determine the effect of treatment in a real-life
clinical setting with a broader range of patients. There are
differences between patients in clinical practice and sub-
jects in clinical trials, suggesting that most clinical practice
patients treated for osteoporosis would not qualify for
participation in the clinical trials that provide the data for
drug approval [10]. In the community cohort of postmen-
opausal women with osteoporosis in the EFOS, we found
that patients prescribed teriparatide in the eight European
participant countries had more severe osteoporosis than
those included in the pivotal trial [8]. This observation
probably reﬂects the European guidelines for osteoporosis
treatment, which recommend teriparatide as a second-line
therapy. Thus, at baseline the mean lumbar spine T-score
BMD was lower in the EFOS (–3.3 SD) than in the pivotal
trial (–2.6 SD), there were more prevalent fractures (mean
2.9 vs. 2.3), and many more patients had received previous
osteoporosis treatment (91.8% vs. 16%), the majority with
potent bisphosphonates. Additionally, a high number of
patients had chronic comorbidities or took concomitant
medications [14] that would have precluded their eligibility
for the pivotal trial [8]. In spite of these differences in
patient characteristics, we found that patients receiving
teriparatide therapy in the EFOS had a signiﬁcant reduction
in the incidence of clinical fractures over time; these results
are consistent with those of the placebo-controlled Fracture
Prevention Trial, where longer treatment duration with
teriparatide was associated with larger reductions in non-
vertebral fracture risk [8, 20]. The fracture risk in patients
receiving treatment after 12–18 months was reduced by
Table 2 Frequency and severity of back pain, limitation of daily activities, and days in bed due to back pain in the last month
Treatment point
Baseline
(n = 1,648)
3 months
(n = 1,467)
6 months
(n = 1,423)
12 months
(n = 1,302)
18 months
(n = 1,200)
Back pain experienced
Yes, n (%) 1,574 (95.5) 1,360 (92.7) 1,297 (91.1) 1,124 (86.3) 1,003 (83.6)
No, n (%) 70 (4.2) 97 (6.6) 112 (7.9) 166 (12.7) 184 (15.3)
Missing/unknown, n (%) 4 (0.2) 10 (0.7) 14 (1.0) 12 (0.9) 13 (1.1)
Frequency of back pain
n 1,574 1,360 1,297 1,124 1,003
Once or twice, n (%) 60 (3.8) 154 (11.3) 209 (16.1) 203 (18.1) 223 (22.2)
A few times, n (%) 156 (9.9) 391 (28.8) 366 (28.2) 315 (28.0) 251 (25.0)
Fairly often, n (%) 288 (18.3) 257 (18.9) 205 (15.8) 171 (15.2) 177 (17.6)
Every day or almost every day, n (%) 1,036 (65.8) 507 (37.3) 451 (34.8) 370 (32.9) 300 (29.9)
Missing/unknown, n (%) 34 (2.2) 51 (3.8) 66 (5.1) 65 (5.8) 52 (5.2)
Severity of back pain
n 1574 1360 1297 1124 1003
Minor, n (%) 139 (8.8) 315 (23.2) 381 (29.4) 370 (32.9) 375 (37.4)
Moderate/severe, n (%) 1,404 (89.2) 997 (73.3) 854 (65.8) 690 (61.4) 574 (57.2)
Missing/unknown, n (%) 31 (2.0) 48 (3.5) 62 (4.8) 64 (5.7) 54 (5.4)
Limitation of activities
n (%) 1,574 1,360 1,297 1,124 1,003
No limitation, n (%) 158 (10.0) 259 (19.0) 319 (24.6) 306 (27.2) 318 (31.7)
Minor, n (%) 237 (15.1) 355 (26.1) 356 (27.4) 304 (27.0) 244 (24.3)
Moderate/severe, n (%) 1,162 (73.8) 718 (52.8) 580 (44.7) 475 (42.3) 413 (41.2)
Missing/unknown, n (%) 17 (1.1) 28 (2.1) 42 (3.2) 39 (3.5) 28 (2.8)
Days in bed due to back pain
None, n (%) 1,237 (75.1) 1,247 (85.0) 1,213 (85.2) 1,055 (81.0%) 950 (79.2)
At least one, n (%) 324 (19.7) 108 (7.4) 78 (5.5) 62 (4.8%) 49 (4.1)
Median (Q1, Q3)
a 7 (3, 15) 4 (2, 10) 3 (2, 6) 3.5 (2, 6) 3 (2, 10)
Missing/unknown, n (%) 87 (5.3) 112 (7.6) 132 (9.3) 185 (14.2%) 201 (16.8)
a For those patients with C1 day in bed due to back pain
All changes: P\0.001 compared to baseline (sign test)
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12347% compared with the ﬁrst 6-month period of treatment.
It was of interest that the fracture risk was already signif-
icantly reduced by 32% in the second 6-month treatment
period (6–12 months) compared with the ﬁrst 6-month
period. A decreased incidence was also observed for clin-
ical vertebral and main nonvertebral fractures.
It is well documented that a prior fracture is a main risk
factor for subsequent fractures in postmenopausal women
with osteoporosis. From the results of two recent meta-
analyses it was concluded that a previous fracture increases
the relative risk (RR) for a subsequent fracture by approx-
imately twofold and a prior vertebral fracture increases the
RR for a subsequent vertebral fracture by fourfold [21, 22].
It has also been demonstrated that subjects who had expe-
rienced a vertebral fracture within the last 12 months had a
ﬁvefold risk of sustaining an additional fracture within the
next year [23]. In the prospective Observational Study of
Severe Osteoporosis (OSSO) study, which included
severely osteoporotic patients treated with various osteo-
porosis medications, women with a fracture within the
12 months prior to baseline were signiﬁcantly more likely
to sustain an incident fracture during the 12-month follow-
up than those without a prior fracture (HR = 1.91,
P\0.001) [24]. In the EFOS cohort, 48% of the patients
had sustained a clinical fragility fracture in the 12 months
before starting teriparatide. However, such a trend toward
an increased risk of additional fractures in these women
with recent prior fractures, compared to those with a prior
fracture that occurred more than 12 months before starting
treatment, was not seen when they were treated with teri-
paratide (HR = 1.37, P = 0.076), which supports the
effectiveness of this drug. This ﬁnding is also in agreement
with data from the Fracture Prevention Trial, where no
increased fracture risk was associated with a larger prior
number and increased severity of fractures in women trea-
ted with teriparatide [25].
Persistence with treatment is a key factor for the efﬁcacy
of any drug in the treatment of osteoporosis [13, 26, 27].
Despite the fact that the administration of teriparatide
involves a once-a-day injection, persistence was relatively
high, with 77% of patients still on treatment after 12 months
and 61.5% after 17 months of treatment. This persistence
was similar to that reported in response to teriparatide
treatment in other recent European [28, 29] and Canadian
[30] studies. The most likely reason for the decline in per-
sistence that we observed between 17 and 18 months
(Fig. 1) is that in most participant European countries
reimbursement only covers 18 pen devices, which corre-
sponds to 504 days of treatment (16.8 months). Observa-
tional studies of various osteoporosis treatments,
particularly oral antiresorptive drugs, have reported 1–
2 year persistence rates of\50% [12, 13, 31, 32]. The high
persistence rate in our study could be explained by several
factors. First, postmenopausal women eligible for teripara-
tide treatment in the EFOS had a mean of approximately
three prevalent fragility fractures and a high prevalence and
severity of back pain, reﬂecting severe osteoporosis [14].
Thus, they may well have perceived a greater beneﬁt-to-risk
ratio than most patients prescribed oral osteoporosis treat-
ments. Many of these patients had received other osteopo-
rosis treatments prior to teriparatide, during which they had
experienced new fractures; therefore, they may have been
very interested in getting the most out of this new treatment
modality. Second, in contrast with other locations, pre-
scription of teriparatide and treatment follow-up in Europe
is largely carried out by specialists and this may have
enhanced compliance. Patients are also aware that they will
receive a course of teriparatide treatment only once. Finally,
most patients were aware that treatment is expensive, which
could have inﬂuenced adherence to the regimen. In the
EFOS, the most common reason for discontinuation of ter-
iparatide was completion of treatment and discontinuations
due to adverse events were low.
The decline in the incidence of fragility fractures was
accompanied by a signiﬁcant reduction in the frequency
and severity of back pain, as well as a clinically relevant
increase in patient-perceived HRQoL. Eighty-nine percent
of women enrolled in the present study reported moderate
or severe back pain at baseline, which had resulted in a
marked deterioration in HRQoL [14]. The reduction in the
frequency and severity of back pain following teriparatide
treatment in these women is consistent with observations
from controlled clinical trials [8, 33]. As expected, the
improvements in back pain and HRQoL were greater in
those subjects who did not present with a new fracture
during the course of the treatment [34, 35]. In meta-
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Fig. 4 Change in HRQoL. EQ-VAS model includes EQ-VAS
baseline value, age, duration of prior bisphosphonate therapies,
rheumatoid arthritis, and history of fracture in the 12 months prior to
starting teriparatide therapy. All values: P\0.001 compared to
baseline. Actual unadjusted values of mean (SD) at 0, 3, 6, 12, and
18 months were 51.7 (22.0), 58.8 (19.9), 61.8 (20.4), 64.8 (22.0), and
68.1 (21.7) mm, respectively
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123analyses of other studies evaluating back pain in osteopo-
rosis, teriparatide-treated patients had a reduced incidence
of back pain compared with placebo- or active comparator–
treated patients [36, 37].
A correlation between the incidence and severity of
fractures due to osteoporosis and HRQoL has been dem-
onstrated in various studies [38–40]. Women with an
inadequate response to osteoporosis therapy and a conse-
quent high rate of further fracture also had a low HRQoL
[24]. In the present study, the reduction in intensity and
frequency of back pain was consistent with the reduction in
the number of days incapacitated, as revealed in the
HRQoL questionnaire. However, it is possible that a pla-
cebo effect and/or the spontaneous resolution of back pain
associated with a recent vertebral fracture could explain the
reduction of 25.8 mm in the VAS observed in the EFOS. In
a recent open, randomized, controlled trial of patients
eligible for a balloon kyphoplasty procedure due to painful
vertebral fractures (baseline VAS[40 mm), the VAS
reduction in the nontreated control group was approxi-
mately 30 mm after 12 months of follow-up [41].
The main strength of observational studies is the
applicability of the results to a general population. The
subjects in the current observational study were drawn
from eight European countries and consisted of patients
with a mixture of health characteristics, and thus, the
results are likely to be relevant to a wide spectrum of
women. In contrast to other reported observational studies
in this area, the incident fractures were conﬁrmed and
validated by the treating physicians. There are limitations
to our study. The collection of adherence and persistence
data by patients’ self-report throughout visits to the clinic
did not include reﬁll dates or take the amount of product
left in the cartridges into consideration. The study was not
Table 3 HRQoL: EQ-5D domains and EQ-5D HSV
Baseline
(n = 1,648)
3 months
(n = 1,467)
6 months
(n = 1,423)
12 months
(n = 1,302)
18 months
(n = 1,200)
Mobility (n [%])
No problem 502 (30.5) 631 (43.0) 687 (48.3) 684 (52.5) 656 (54.7)
Some problem 1,080 (65.5) 774 (52.8) 684 (48.1) 577 (44.3) 495 (41.3)
Extreme problem 51 (3.1) 12 (0.8) 8 (0.6) 7 (0.5) 6 (0.5)
Missing/unknown 15 (0.9) 50 (3.4) 44 (3.1) 34 (2.6) 43 (3.6)
Self-care (n [%])
No problem 924 (56.1) 978 (66.7) 1005 (70.6) 958 (73.6) 883 (73.6)
Some problem 619 (37.6) 405 (27.6) 340 (23.9) 276 (21.2) 245 (20.4)
Extreme problem 85 (5.2) 38 (2.6) 32 (2.2) 33 (2.5) 31 (2.6)
Missing/unknown 20 (1.2) 46 (3.1) 46 (3.2) 35 (2.7) 41 (3.4)
Usual activities (n [%])
No problem 385 (23.4) 496 (33.8) 594 (41.7) 572 (43.9) 583 (48.6)
Some problem 999 (60.6) 822 (56.0) 693 (48.7) 619 (47.5) 506 (42.2)
Extreme problem 245 (14.9) 95 (6.5) 88 (6.2) 74 (5.7) 69 (5.8)
Missing/unknown 19 (1.2) 54 (3.7) 48 (3.4) 37 (2.8) 42 (3.5)
Pain/discomfort (n [%])
No problem 122 (7.4) 216 (14.7) 286 (20.1) 302 (23.2) 335 (27.9)
Some problem 992 (60.2) 1036 (70.6) 966 (67.9) 857 (65.8) 725 (60.4)
Extreme problem 505 (30.6) 164 (11.2) 115 (8.1) 106 (8.1) 95 (7.9)
Missing/unknown 29 (1.8) 51 (3.5) 56 (3.9) 37 (2.8) 45 (3.8)
Anxiety/depression (n [%])
No problem 685 (41.6) 722 (49.2) 763 (53.6) 716 (55.0) 682 (56.8)
Some problem 716 (43.4) 603 (41.1) 534 (37.5) 470 (36.1) 425 (35.4)
Extreme problem 228 (13.8) 92 (6.3) 79 (5.6) 81 (6.2) 51 (4.3)
Missing/unknown 19 (1.2) 50 (3.4) 47 (3.3) 35 (2.7) 42 (3.5)
EQ-5D HSV
n 1599 1401 1357 1259 1151
Median (Q1, Q3) 0.59 (0.08, 0.73) 0.69 (0.52, 0.76) 0.69 (0.52, 0.80) 0.69 (0.59, 0.80) 0.73 (0.59, 0.85)
Missing/unknown (n [%]) 49 (3.0) 66 (4.5) 66 (4.6) 43 (3.3%) 49 (4.1)
All changes: P\0.001 compared to baseline (sign test) or Wilcoxon signed rank test for EQ-5D HSV
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123designed to formally analyze safety data or to include
centralized evaluation of clinical laboratory abnormal
ﬁndings. Thus, only spontaneous adverse events were
collected and analyzed. The analysis of fracture incidence
was based only on the number of patients who fractured in
a given time and did not consider multiple fractures in the
same time period. Finally, the lack of a randomized control
group also limited us from making any deﬁnite conclusions
regarding the impact of the treatment on the fracture
reduction risk and the patient subjective reported outcomes.
In conclusion, it has been shown in the EFOS study that
18 months of treatment with teriparatide is an effective
therapeutic option for postmenopausal women with severe
osteoporosis in a real-life clinical setting, characterized by
highly prevalent comorbidities and concomitant medica-
tions. The EFOS results conﬁrm and expand the outcomes
reported for the more selective patient populations included
in the randomized controlled trials of teriparatide. Never-
theless, these results should be interpreted in the context of
the open-label, noncontrolled design of the study.
Compliance with the treatment regimen was high and
teriparatide was well tolerated. There was a reduction in
the number and severity of clinical fractures, back pain was
reduced, and there was an overall beneﬁcial effect on
HRQoL. Further studies are necessary to monitor the long-
term outcomes of teriparatide treatment and effects on
health-related costs.
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Appendix 1: EFOS Back Pain Questionnaire
Back Pain Evaluation in the Last Month
Not applicable (No back pain within the last month)
1. During the last month, how often did the patient
experience back pain?
o Once or twice
o A few times
o Fairly often
o Every day or almost every day
2. During the last month, how would you rate the
severity of the patient’s back pain?
o Minor
o Moderate
o Severe
3. During the last month, to what extent has the patient’s
activities been limited (please tick one response)?
o No limitation
o Minor extent
o Moderate extent
o Severe extent
4. During the last month, how many days did the patient
stay in bed because of back pain? (Please indicate ‘‘0’’
if none).
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